title: Comparison of effects of nisoldipine-extended release and amlodipine in patients with systemic hypertension and chronic stable angina pectoris.
abstract: The efficacy and safety of nisoldipine-extended release (ER) and amlodipine were compared in a 6-week multicenter, randomized, double-blind, double-dummy, parallel group, titration-to-effect trial in patients with stage 1 to 2 systemic hypertension (90 to 109 mm Hg diastolic blood pressure [BP]) and chronic stable angina pectoris. After a 3-week placebo run-in period, patients (n = 120) were randomly assigned to active treatment with either nisoldipine-ER (20 to 40 mg) or amlodipine (5 to 10 mg) once daily, titrated as necessary after 2 weeks to achieve diastolic BP <90 mm Hg. After 6 weeks, the mean reduction in systolic/diastolic BP from baseline was 15/13 mm Hg with nisoldipine-ER and 13/11 mm Hg with amlodipine (p = NS/p = NS). Both drugs resulted in similar BP responder rates (diastolic BP <90 mm Hg in 87% of patients who received nisoldipine-ER and 78% of patients on amlodipine, p = NS) and anti-ischemic responder rates (increasing exercise time >20% in 20% and 27%, respectively [p = NS], and increasing exercise time >60 seconds in 32% and 29% of patients, respectively [p = NS]. Also, after 6 weeks of active therapy, there was a similar mean increase in total exercise duration (23 seconds in the nisoldipine-ER group and 21 seconds in the amlodipine group, p = NS). Neither drug increased heart rate and both decreased frequency of anginal episodes. Adverse events were infrequent, and typically were vasodilator-related effects (including headache and peripheral edema) that occurred with somewhat higher incidence in the nisoldipine-ER group. Thus, nisoldipine-ER and amlodipine provided comparable antihypertensive and anti-ischemic efficacy, and both were generally well tolerated.
authors.affiliation: University of Florida College of Medicine, Gainesville, Florida 32610, USA.
authors.forename: Carl J
authors.initials: CJ
authors.lastname: Pepine
authors.forename: Rhonda M
authors.initials: RM
authors.lastname: Cooper-DeHoff
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Weiss
authors.forename: Michael
authors.initials: M
authors.lastname: Koren
authors.forename: Neville
authors.initials: N
authors.lastname: Bittar
authors.forename: Udho
authors.initials: U
authors.lastname: Thadani
authors.forename: Margaret C
authors.initials: MC
authors.lastname: Minkwitz
authors.forename: Eric L
authors.initials: EL
authors.lastname: Michelson
authors.forename: Howard G
authors.initials: HG
authors.lastname: Hutchinson
mesh_terms: D017311:Amlodipine / Q000009:adverse effects / Q000627:therapeutic use*; D000787:Angina Pectoris / Q000150:complications / Q000188:drug therapy*; D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D005080:Exercise Test; D005260:Female; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D015737:Nisoldipine / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D002121:Calcium Channel Blockers; D003692:Delayed-Action Preparations; D017311:Amlodipine; D015737:Nisoldipine